BriMindInvest Logo

Intuitive Surgical Inc. (ISRG) Stock Analysis 2026

Medical DevicesRobotic Surgery & Surgical Instruments
$378.81
as of 2026-08-07

BriMind AI Score

Proprietary
50
Neutral
Price CAGR
16.5%
1Y Return
-26.9%
Analyst Upside
+35.1%
Rev Growth
18.5%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$323.62-14.6% potential
Bear Case
$186.56
Bull Case
$505.83
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

About Intuitive Surgical Inc.

Intuitive Surgical is the undisputed leader in robotic-assisted surgery, with its da Vinci surgical system installed in 9,000+ hospitals worldwide. The company's robots assist surgeons in performing minimally invasive procedures across urology (prostatectomy), gynecology (hysterectomy), general surgery (hernia repair, cholecystectomy), and thoracic surgery. Intuitive launched the next-generation da Vinci 5 system in 2024, its most significant platform upgrade in a decade.

How Intuitive Makes Money

Intuitive earns from a razor-and-blade model: system placements (~17% of revenue — da Vinci robots cost $1-2.5M each), instruments and accessories (~55% — single-use instruments consumed per procedure, $700-3,500 per procedure), and services (~28% — maintenance contracts and training). The recurring instruments and services revenue is the key to the business — once a hospital buys a robot, it generates decades of consumable revenue.

Intuitive Revenue & Profitability Breakdown

This chart shows how Intuitive's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$11.03B
Cost of Revenue
-$3.68B
Gross Profit
$7.36B66.7% margin
Operating Expenses
-$3.65B
Operating Income
$3.71B33.6% margin
Tax & Other
-$569.0M
Net Income
$3.14B28.4% margin
Gross Margin
66.7%
Operating Margin
33.6%
Net Margin
28.4%
EBITDA Margin
34.0%

Key Financial Metrics

A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.

Market Cap
$126.59B
Enterprise Value
$195.26B
P/E (Trailing)
40.47
P/E (Forward)
29.27
EV / EBITDA
65.83
Price / Sales
22.91
Price / Book
11.67
Revenue
$11.03B
Revenue Growth
18.5%
Earnings Growth
26.5%
EBITDA
$2.97B
Gross Margin
66.7%
Operating Margin
33.6%
Net Margin
28.4%
Return on Equity
17.4%
Return on Assets
10.5%
Free Cash Flow
$2.62B
Total Cash
$4.51B
Total Debt
$0
Debt / Equity
0.95
Current Ratio
4.96
Quick Ratio
3.64
Beta
1.46
Dividend Yield
None
Payout Ratio
0.0%
Book Value / Share
$51.34

Wall Street Analyst Consensus

Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.

Consensus RatingBuy(28 analysts)
SellStrong Buy
Low Target$350.00-7.6%
Mean Target$477.25+26.0% upside
High Target$675.00+78.2%

Intrinsic Value Estimates for ISRG

Intrinsic value is what a stock is truly worth based on the company's fundamentals — independent of what the market currently prices it at. We use multiple models because no single formula is perfect: each captures different aspects of a business. If multiple models agree the stock is undervalued, that convergence is a stronger signal. A stock trading well below its intrinsic value may be a bargain; one far above may carry more risk.

DCF Model (10yr)
$153.23
-59.6% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$153.23 – $153.23
Average Estimate
$153.23
Potential Downside
-59.6%

⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

ISRG Investment Case: Bull vs Bear

Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Bull Case (Reasons to Buy)

  • da Vinci 5 is a generational upgrade — force feedback, AI-powered insights, and improved ergonomics should accelerate adoption and expand into new procedure types.
  • Only 3-5% of addressable procedures are performed robotically — the penetration runway is enormous, particularly in general surgery and international markets.
  • Installed base of 9,000+ systems generates $6B+ in recurring instruments and services revenue — a durable, growing annuity stream.
  • First-mover advantage with 25+ years of surgeon training creates switching costs — surgeons trained on da Vinci are reluctant to switch to competing platforms.

Bear Case (Key Risks)

  • Valuation is extreme — at 60-70x forward P/E, Intuitive is priced for flawless execution over many years.
  • Competition is intensifying — Medtronic (Hugo), J&J (Ottava), and Stryker are developing surgical robots that could erode Intuitive's monopoly.
  • da Vinci 5 transition may cannibalize da Vinci Xi placements in the near term as hospitals wait for the new system.
  • Hospital capital budgets are pressured — expensive robotic systems ($1-2.5M) face scrutiny when hospital margins are thin.

What to Watch: ISRG Key Metrics

da Vinci procedure growth
da Vinci 5 system placements
Instruments & accessories revenue per procedure
Installed base growth
International market expansion

ISRG Stock — Frequently Asked Questions

Compare ISRG with Peers

ISRG vs MDTIntuitive Surgical vs Medtronic — Which Medical Device
BSX vs ISRGBoston Scientific vs Intuitive Surgical — Which MedTech
ISRG vs SYKIntuitive Surgical vs Stryker — Which MedTech Robot Sto
ISRG vs GEHCIntuitive Surgical vs GE HealthCare — Robotic Surgery v
ISRG vs NVCRIntuitive Surgical vs NovaCure — Robotic Surgery vs Ele
EDAP vs IRTCiRhythm vs Inspire Medical — Cardiac Monitoring vs Slee
ISRG vs ABTIntuitive Surgical vs Abbott — Which Medtech Stock Wins
PEN vs ISRGPenumbra vs Intuitive Surgical — Neurovascular vs Robot

ISRG — Related Investment Themes

Top Robotics Stocks8 stocks in themeTop Humanoid Robot Stocks8 stocks in theme

Unlock the Full ISRG Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
← Back to Home · Browse All Stock Analysis

We use cookies to keep you signed in and to understand how people use our site (Google Analytics). You can accept all cookies or limit them to what's strictly necessary. Privacy policy